# Pan-Cancer Protocol Optimization — Hypothetical Results (SAEM, 10 Cancer Types)

> ⚠️ **COMPUTATIONAL HYPOTHESIS ONLY** — These results are from in silico simulations with no experimental validation. See [DISCLAIMER.md](../DISCLAIMER.md).

> **Framework:** Geometric Achievement Protocol with adaptive resistance-aware phasing
> **Cancer Types:** 10 | **Trials per cancer:** 100 MC + 200 bootstrap | **Date:** Auto-generated

## 1) Seriousness Ranking (Component Breakdown)

| Rank | Cancer | Composite | Coherence Deficit | Basin Curvature | Immune Suppression | Stress Load | Stromal Barrier |
|---:|---|---:|---:|---:|---:|---:|---:|
| 1 | **PDAC** | 0.4939 | 0.4377 | 0.1898 | 0.8000 | 0.3000 | 0.8500 |
| 2 | **HCC** | 0.4821 | 0.4453 | 0.1624 | 0.6000 | 0.8750 | 0.5000 |
| 3 | **GBM** | 0.4346 | 0.4223 | 0.1840 | 0.7000 | 0.5238 | 0.4000 |
| 4 | **HGSOC** | 0.4272 | 0.4134 | 0.1988 | 0.5000 | 0.5789 | 0.5500 |
| 5 | **TNBC** | 0.3898 | 0.4147 | 0.2045 | 0.5500 | 0.5000 | 0.3000 |
| 6 | **AML** | 0.3864 | 0.4082 | 0.2087 | 0.4500 | 0.7143 | 0.2000 |
| 7 | **mCRPC** | 0.3839 | 0.4170 | 0.2052 | 0.6500 | 0.2727 | 0.3500 |
| 8 | **CRC** | 0.3468 | 0.3984 | 0.2267 | 0.4000 | 0.4000 | 0.3000 |
| 9 | **Melanoma** | 0.3351 | 0.3795 | 0.2573 | 0.2000 | 0.7143 | 0.1500 |
| 10 | **NSCLC** | 0.3291 | 0.4109 | 0.2148 | 0.3500 | 0.4000 | 0.2500 |

## 2) Per-Cancer Tailored Protocols

### PDAC
- **Flatten** (32d) → **Heat** (9d) → **Push** (32d) = 73d total
- **Drugs:** 2-Deoxyglucose (2-DG) (established), CB-839 (Telaglenastat) (emerging), Epogen (Epoetin alfa) (warning), Anti-PD-1 (Pembrolizumab) (established)
- **Rationale:** Composite seriousness 0.4939; immune suppression=0.80, stromal barrier=0.85

### HCC
- **Flatten** (30d) → **Heat** (8d) → **Push** (31d) = 69d total
- **Drugs:** Epogen (Epoetin alfa) (warning), 2-Deoxyglucose (2-DG) (established), CB-839 (Telaglenastat) (emerging), Anti-PD-1 (Pembrolizumab) (established)
- **Rationale:** Composite seriousness 0.4821; immune suppression=0.60, stromal barrier=0.50

### GBM
- **Flatten** (26d) → **Heat** (7d) → **Push** (27d) = 60d total
- **Drugs:** 2-Deoxyglucose (2-DG) (established), Epogen (Epoetin alfa) (warning), Anti-PD-1 (Pembrolizumab) (established), Anti-CTLA-4 (Ipilimumab) (established)
- **Rationale:** Composite seriousness 0.4346; immune suppression=0.70, stromal barrier=0.40

### HGSOC
- **Flatten** (26d) → **Heat** (7d) → **Push** (27d) = 60d total
- **Drugs:** Epogen (Epoetin alfa) (warning), 2-Deoxyglucose (2-DG) (established), CB-839 (Telaglenastat) (emerging), Dichloroacetate (DCA) (established)
- **Rationale:** Composite seriousness 0.4272; immune suppression=0.50, stromal barrier=0.55

### TNBC
- **Flatten** (23d) → **Heat** (6d) → **Push** (24d) = 53d total
- **Drugs:** 2-Deoxyglucose (2-DG) (established), Epogen (Epoetin alfa) (warning), CB-839 (Telaglenastat) (emerging), Anti-PD-1 (Pembrolizumab) (established)
- **Rationale:** Composite seriousness 0.3898; immune suppression=0.55, stromal barrier=0.30

### AML
- **Flatten** (22d) → **Heat** (6d) → **Push** (24d) = 52d total
- **Drugs:** Epogen (Epoetin alfa) (warning), 2-Deoxyglucose (2-DG) (established), CB-839 (Telaglenastat) (emerging), Dichloroacetate (DCA) (established)
- **Rationale:** Composite seriousness 0.3864; immune suppression=0.45, stromal barrier=0.20

### mCRPC
- **Flatten** (22d) → **Heat** (6d) → **Push** (23d) = 51d total
- **Drugs:** Epogen (Epoetin alfa) (warning), 2-Deoxyglucose (2-DG) (established), Anti-PD-1 (Pembrolizumab) (established), Anti-CTLA-4 (Ipilimumab) (established)
- **Rationale:** Composite seriousness 0.3839; immune suppression=0.65, stromal barrier=0.35

### CRC
- **Flatten** (19d) → **Heat** (5d) → **Push** (21d) = 45d total
- **Drugs:** 2-Deoxyglucose (2-DG) (established), Epogen (Epoetin alfa) (warning), Dichloroacetate (DCA) (established), Vorinostat (SAHA, HDACi) (established)
- **Rationale:** Composite seriousness 0.3468; immune suppression=0.40, stromal barrier=0.30

### Melanoma
- **Flatten** (18d) → **Heat** (5d) → **Push** (20d) = 43d total
- **Drugs:** Epogen (Epoetin alfa) (warning), 2-Deoxyglucose (2-DG) (established), NAD+ Precursors (NMN/NR) (emerging), CB-839 (Telaglenastat) (emerging)
- **Rationale:** Composite seriousness 0.3351; immune suppression=0.20, stromal barrier=0.15

### NSCLC
- **Flatten** (18d) → **Heat** (5d) → **Push** (20d) = 43d total
- **Drugs:** Epogen (Epoetin alfa) (warning), 2-Deoxyglucose (2-DG) (established), CB-839 (Telaglenastat) (emerging), Dichloroacetate (DCA) (established)
- **Rationale:** Composite seriousness 0.3291; immune suppression=0.35, stromal barrier=0.25

## 3) Cure Metrics with Uncertainty

| Cancer | Escape Distance | Cure Rate | 95% CI | Robustness | Resist-Adj Escape Rate |
|---|---:|---:|---|---:|---:|
| **PDAC** | 0.439 | 100.0% | [100.0%, 100.0%] | 0.883 | 0.3047 |
| **HCC** | 0.436 | 100.0% | [100.0%, 100.0%] | 0.885 | 0.3040 |
| **GBM** | 0.280 | 100.0% | [100.0%, 100.0%] | 0.926 | 0.2999 |
| **HGSOC** | 0.515 | 100.0% | [100.0%, 100.0%] | 0.872 | 0.2908 |
| **TNBC** | 0.408 | 100.0% | [100.0%, 100.0%] | 0.900 | 0.3062 |
| **AML** | 0.543 | 100.0% | [100.0%, 100.0%] | 0.870 | 0.2974 |
| **mCRPC** | 0.271 | 100.0% | [100.0%, 100.0%] | 0.926 | 0.2770 |
| **CRC** | 0.480 | 100.0% | [100.0%, 100.0%] | 0.890 | 0.2973 |
| **Melanoma** | 0.440 | 100.0% | [100.0%, 100.0%] | 0.896 | 0.2837 |
| **NSCLC** | 0.447 | 100.0% | [100.0%, 100.0%] | 0.893 | 0.2975 |

## 4) Resistance Comparison (Adaptive vs Continuous)

| Cancer | Adaptive Escape Dist | Continuous Escape Dist | Winner | Advantage |
|---|---:|---:|---|---:|
| **PDAC** | 0.4656 | 0.9629 | Adaptive | +0.4973 |
| **HCC** | 0.4148 | 0.8793 | Adaptive | +0.4645 |
| **GBM** | 0.2953 | 0.7819 | Adaptive | +0.4866 |
| **HGSOC** | 0.5168 | 0.7356 | Adaptive | +0.2188 |
| **TNBC** | 0.4132 | 0.7002 | Adaptive | +0.2870 |
| **AML** | 0.5313 | 0.6777 | Adaptive | +0.1464 |
| **mCRPC** | 0.2608 | 0.6297 | Adaptive | +0.3689 |
| **CRC** | 0.4508 | 0.6114 | Adaptive | +0.1606 |
| **Melanoma** | 0.3645 | 0.5128 | Adaptive | +0.1483 |
| **NSCLC** | 0.3828 | 0.5607 | Adaptive | +0.1779 |

## 5) Sensitivity Analysis (Representative Cancer)

| Parameter | Escape Distance | Delta from Baseline |
|---|---:|---:|
| base_force_0.5x | 0.539 | +0.121 |
| base_force_1.0x | 0.418 | +0.000 |
| base_force_1.5x | 0.339 | -0.079 |
| noise_scale_0.5x | 0.138 | -0.280 |
| noise_scale_1.0x | 0.418 | +0.000 |
| noise_scale_2.0x | 1.077 | +0.659 |

## 6) Coherence Restoration

| Cancer | Baseline Coherence | Post-Treatment | Healthy Target |
|---|---:|---:|---:|
| **PDAC** | 0.5623 | 0.6362 | 1.0000 |
| **HCC** | 0.5547 | 0.6416 | 1.0000 |
| **GBM** | 0.5777 | 0.6440 | 1.0000 |
| **HGSOC** | 0.5866 | 0.6711 | 1.0000 |
| **TNBC** | 0.5853 | 0.6508 | 1.0000 |
| **AML** | 0.5918 | 0.6654 | 1.0000 |
| **mCRPC** | 0.5830 | 0.6479 | 1.0000 |
| **CRC** | 0.6016 | 0.6625 | 1.0000 |
| **Melanoma** | 0.6205 | 0.6691 | 1.0000 |
| **NSCLC** | 0.5891 | 0.6686 | 1.0000 |

## 7) Failure Modes & Limitations

- **10D approximation:** Real tumors have spatial gradients, clonal heterogeneity, and epigenetic state spaces beyond 10 metabolites.
- **Drug additivity:** Generator corrections are summed linearly; real synergy/antagonism may differ.
- **Resistance model:** Exponential decay (τ=15d) is a simplified proxy for complex tumor rewiring.
- **Immune exhaustion:** Single-compartment model; real T-cell dynamics involve trafficking, priming, and tissue-specific barriers.
- **No pharmacokinetics in MC:** Monte Carlo uses constant-dose phases rather than time-weighted PK curves.
- **Stromal coupling:** Modeled as a scalar metadata field; actual microenvironment interactions are spatially resolved.

## 8) Final Verdict & Gate Outcomes

- **Simulated Escape Threshold (≥90% per cancer):** ✅ PASS — 10/10 cancers achieve ≥90% simulated escape rate
- **Adaptive Superiority:** ✅ PASS — Adaptive beats continuous in 10/10 cancers
- **Protocol Diversity:** ✅ PASS — 5/10 unique drug combinations (min 5 required)
- **Non-Uniform Outcomes:** ✅ PASS — Escape distance range: [0.271, 0.543]

### 🏆 ALL GATES PASSED — Pan-cancer geometric escape hypothesis validated computationally across 10 types.

> **Note:** "Validated" refers to computational validation only. Experimental wet-lab validation has not been performed.
